Modulation of Amyloid-β42 Conformation by Small Molecules Through Nonspecific Binding

Area of Science:

• Computational Chemistry and Molecular Modeling
• Neuroscience and Neurodegenerative Diseases
• Pharmacology and Drug Discovery

Background:

• Amyloid-beta (Aβ) peptide aggregation is a critical pathological hallmark in Alzheimer's disease (AD) progression.
• Developing effective inhibitors for Aβ aggregation remains a significant challenge in AD therapeutic research.

Purpose of the Study:

• To investigate the atomistic mechanisms by which homotaurine and scyllo-inositol inhibit Aβ aggregation.
• To provide molecular-level insights into the design of novel therapeutic agents for Alzheimer's disease.

Main Methods:

• Utilized atomistic simulations to study the interaction between Aβ42 monomers and the small molecules homotaurine and scyllo-inositol.
• Analyzed conformational changes induced in Aβ42 monomers upon binding with the candidate inhibitors.

Main Results:

• Both homotaurine and scyllo-inositol were shown to induce a conformational shift in the Aβ42 monomer.
• This conformational change favors a more collapsed state of the Aβ42 monomer, suggesting an inhibition mechanism.
• The binding mechanism was characterized as nonspecific, highlighting a general interaction mode.

Conclusions:

• Homotaurine and scyllo-inositol act as potential inhibitors of Aβ aggregation through monomer destabilization.
• The findings offer crucial atomistic details for the rational design of future Alzheimer's disease drug candidates.